Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
6.68
+1.91 (40.04%)
At close: Dec 20, 2024, 4:00 PM
6.90
+0.22 (3.29%)
After-hours: Dec 20, 2024, 7:55 PM EST
Company Description
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States.
The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product.
The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed N.V.
| Country | Germany |
| Founded | 2021 |
| IPO Date | Nov 5, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Guido Baechler |
Contact Details
Address: Robert Koch Strasse 50 Mainz, 55129 Germany | |
| Phone | 49 6131 554 2860 |
| Website | mainzbiomed.com |
Stock Details
| Ticker Symbol | MYNZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001874252 |
| CUSIP Number | N5436L101 |
| ISIN Number | NL0015000LC2 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Guido Baechler | Chief Executive Officer and Executive Director |
| William J. Caragol C.P.A. | Chief Financial Officer |
| Dr. Christopher Von Torne P.M.P., Ph.D. | Chief Operating Officer |
| Dr. Frank Krieg-Schneider | Chief Technology Officer |
| Dr. Moritz Eidens Ph.D. | Chief Science Officer and Executive Director |
| Stefan Erlach | Head of Human Resources |
| Philipp Freese | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 6-K | Report of foreign issuer |
| Dec 16, 2024 | 424B3 | Prospectus |
| Dec 13, 2024 | 6-K | Report of foreign issuer |
| Dec 12, 2024 | EFFECT | Notice of Effectiveness |
| Dec 11, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 9, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 9, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Nov 29, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |